TABLE 2.
Antiviral potency against HCV genotypes 1 to 5
| Genotype | Virus/replicona | Mean EC50 ± SD (pM) ofb: |
|
|---|---|---|---|
| Samatasvir | Daclatasvir | ||
| 1a | H1a-luc | 4.1 ± 1.1 | 51 ± 11 |
| 100-IGT | 8.5 ± 1.7 | 84 ± 27 | |
| FL-IGT | 6.2 ± 1.7 | 80 ± 33 | |
| 1b | Zluc | 2.4 ± 0.6 | 13 ± 4 |
| 2a | JFH-1 virus | 21 ± 4 | 158 ± 50 |
| FL-IGT | 24 ± 4 | 176 ± 1 | |
| 3a | 100-IGT | 23 ± 11 | 1,086 ± 301 |
| FL-IGT | 17 ± 3 | 299 ± 4 | |
| 4a | 100-IGT | 6.0 ± 0.1 | 72 ± 66 |
| FL-IGT | 2.0 ± 0 | 19 ± 3 | |
| 5a | 100-IGT | 18 ± 2 | 42 ± 1 |
a
100-IGT, ZS11-luc replicon containing intergenotypic substitutions in amino acids 1 to 100 of NS5A; FL-IGT, ZS11-luc replicon containing intergenotypic substitutions in amino acids 12 to 437 of NS5A.
b
Data are from 3 to 5 independent experiments.